The DOI matches its Crossref record; 27 of the 29 references it cites were found in a registry or an index.
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Abstract
Background Nanoliposomal irinotecan showed activity in a phase 2 study in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapies. We assessed the effect of nanoliposomal irinotecan alone or combined with fluorouracil and folinic acid in a phase 3 trial in this population.Methods We did a global, phase 3, randomised, open-label trial at 76 sites in 14 countries. Eligible patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy were randomly assigned (1:1) using an interactive web response system at a central location to receive either nanoliposomal irinotecan monotherapy (120 mg/m(2) every 3 weeks, equivalent to 100 mg/m(2) of irinotecan base) or fluorouracil and folinic acid. A third arm consisting of nanoliposomal irinotecan (80 mg/m(2), equivalent to 70 mg/m(2) of irinotecan base) with fluorouracil and folinic acid every 2 weeks was added later (1:1:1), in a protocol amendment. Randomisation was stratified by baseline albumin, Karnofsky performance status, and ethnic origin. Treatment was continued until disease progression or intolerable toxic effects. The primary endpoint was overall survival, assessed in the intention-to-treat population. The primary analysis was planned after 305 events. Safety was assessed in all patients who had received study drug. This trial is registered at ClinicalTrials.gov, number NCT01494506.Findings Between Jan 11, 2012, and Sept 11, 2013, 417 patients were randomly assigned either nanoliposomal irinotecan plus fluorouracil and folinic acid (n=117), nanoliposomal irinotecan monotherapy (n=151), or fluorouracil and folinic acid (n=149). After 313 events, median overall survival in patients assigned nanoliposomal irinotecan plus fluorouracil and folinic acid was 6.1 months (95% CI 4.8-8.9) vs 4.2 months (3.3-5.3) with fluorouracil and folinic acid (hazard ratio 0.67, 95% CI 0.49-0.92; p=0.012). Median overall survival did not differ between patients assigned nanoliposomal irinotecan monotherapy and those allocated fluorouracil and folinic acid (4.9 months [4.2-5.6] vs 4.2 months [3.6-4.9]; 0.99, 0.77-1.28; p=0.94). The grade 3 or 4 adverse events that occurred most frequently in the 117 patients assigned nanoliposomal irinotecan plus fluorouracil and folinic acid were neutropenia (32 [27%]), diarrhoea (15 [13%]), vomiting (13 [11%]), and fatigue (16 [14%]).Interpretation Nanoliposomal irinotecan in combination with fluorouracil and folinic acid extends survival with a manageable safety profile in patients with metastatic pancreatic ductal adenocarcinoma who previously received gemcitabine-based therapy. This agent represents a new treatment option for this population.Funding Merrimack Pharmaceuticals.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients progressing on first-line regimens can be offered the possibility of switching to the other regimen, or a second-line regimen that includes a liposomal formulation of irinotecan in combination with 5-FU10, provided they have not received either of these agents previously.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [10]
Citations
Cites
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Self-citationIncreased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Self-citationBurris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,895
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Oettle, H., Riess, H. B., Stieler, J., Heil, G., Schwaner, I., Seraphin, J., Görner, M., Mölle, M., Greten, T. F., Lakner, V., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.6995 · Cited by 492
Self-citationKalra, A. V., Kim, J., Klinz, S. G., Paz, N., Cain, J. E., Drummond, D. C., Nielsen, U. B., & Fitzgerald, J. B. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0572 · Cited by 199
Self-citationPharmacogenetics of irinotecan metabolism and transport: An update
Smith, N. F., Figg, W. D., & Sparreboom, A. (2005) · Toxicology in Vitro · doi:10.1016/j.tiv.2005.06.045 · Cited by 190
Yoo, C., Hwang, J. Y., Kim, J. H., Kim, T. W., Lee, J. S., Park, D. H., Lee, S. K., Seo, D. W., Lee, S. S., Kim, M., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605374 · Cited by 169
Self-citationKo, A. H., Tempero, M. A., Shan, Y.-S., Su, W., Lin, Y.-L., Dito, E., Ong, A., Wang, Y.-W., Yeh, C. G., & Chen, L.-T. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.408 · Cited by 160
Self-citationRoy, A. C., Park, S. R., Cunningham, D., Kang, Y., Chao, Y., Chen, L., Rees, C., Lim, H. Y., Tabernero, J. M., Ramos, F. J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt002 · Cited by 123
Self-citation
Cited by
Sorted by citations
Items 101–200 of 1,000
Consensus, debate, and prospective on pancreatic cancer treatments
Wang, J., Yang, J., Narang, A. K., He, J., Wolfgang, C. L., Li, K., & Zheng, L. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01613-x · Cited by 104
Fang, Y., Mo, F., Shou, J., Wang, H., Luo, K., Zhang, S., Han, N., Li, H., Ye, S., Zhou, Z. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2881 · Cited by 98
Self-citationAmpullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology
Chiorean, E. G., Chiaro, M. D., Tempero, M. A., Malafa, M. P., Benson, A. B., Cardin, D. B., Christensen, J. A., Chung, V. M., Czito, B. G., Dillhoff, M. E., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0034 · Cited by 102
Self-citationTumor microenvironment targeted nano-drug delivery systems for multidrug resistant tumor therapy
Shao, X., Zhao, X., Wang, B., Fan, J., Wang, J., & An, H. (2025) · Theranostics · doi:10.7150/thno.103636 · Cited by 101
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
Yousef, A., Yousef, M., Chowdhury, S., Abdilleh, K., Knafl, M., Edelkamp, P., Alfaro-Munoz, K., Chacko, R., Peterson, J., Smaglo, B. G., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00505-0 · Cited by 93
Self-citationLipid-Based Nanotechnology: Liposome
Jiang, Y., Li, W., Wang, Z., & Lu, J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010034 · Cited by 102
“Another clinical report also stated that Nyotran was active in some patients in which Amphotericin B treatment failed [158].”
BackgroundBockorny, B., Macarulla, T., Semenisty, V., Borazanci, E., Feliu, J., Ponz-Sarvise, M., Abad, D. G., Oberstein, P., Alistar, A., Muñoz, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0929 · Cited by 92
“The observed safety profile of triple combination therapy was consistent with the profile observed in the NAPOLI-1 regimen with key distinctions (5).”
BackgroundResultInfluentialSelf-citationSystemic Therapy for Metastatic Pancreatic Cancer
Ettrich, T. J., & Seufferlein, T. T. W. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00895-4 · Cited by 94
Self-citationNano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions
Giordano, G., Pancione, M., Olivieri, N., Parcesepe, P., Velocci, M., Raimo, T. D., Coppola, L., Toffoli, G., & D'Andrea, M. R. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i32.5875 · Cited by 93
Glassman, D. C., Palmaira, R. L. D., Covington, C. M., Desai, A. M., Ku, G. Y., Li, J., Harding, J. J., Varghese, A. M., O'Reilly, E. M., & Yu, K. H. (2018) · BMC Cancer · doi:10.1186/s12885-018-4605-1 · Cited by 89
“[8] NAPOLI-1 was a global study which enrolled 417 patients who previously received Gem-based chemotherapy.”
BackgroundLiposomal Cytarabine as Cancer Therapy: From Chemistry to Medicine
Salehi, B., Selamoğlu, Z., Mileski, K. S., Pezzani, R., Redaelli, M., Cho, W. C. S., Kobarfard, F., Rajabi, S., Martorell, M., Kumar, P., et al. (2019) · Biomolecules · doi:10.3390/biom9120773 · Cited by 90
Chiorean, E. G., Hoff, D. D. V., Tabernero, J. M., El-Maraghi, R. H., Ma, W. W., Reni, M., Harris, M., Whorf, R. C., Liu, H. W., Li, J. S., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.185 · Cited by 90
Self-citationSafety Considerations of Cancer Nanomedicine—A Key Step toward Translation
Liu, X., Tang, I., Wainberg, Z. A., & Meng, H. (2020) · Small · doi:10.1002/smll.202000673 · Cited by 90
Kras and tumor immunity: friend or foe?
Cullis, J., Das, S., & Bar-Sagi, D. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031849 · Cited by 85
“Following up on these promising results, the CCR2 inhibitor PF-04136309 in combination with the chemotherapeutic regimen FOLFIRINOX is currently in clinical trials, with phase 1b results revealing 52% partial response and 47.8% of patients showing stable disease (Wang-Gillam et al. 2016).”
BackgroundInfluentialBHANGE, M. A., & Telange, D. R. (2025) · Discover Oncology · doi:10.1007/s12672-025-01821-y · Cited by 105
Pancreas Cancer-Associated Pain Management
Coveler, A. L., Mizrahi, J. D., Eastman, B., Apisarnthanarax, S., Dalal, S., McNearney, T. A., & Pant, S. (2021) · The Oncologist · doi:10.1002/onco.13796 · Cited by 86
“In the NAPOLI-I trial, fluorouracil + leucovorin + nanoliposomal irinotecan demonstrated a survival benefit in patients pretreated with gemcitabine-based chemotherapy compared with 5-FU + leucovorin [33].”
Self-citationPancreatic Adenocarcinoma Management
Jiang, Y., & Sohal, D. P. S. (2022) · JCO Oncology Practice · doi:10.1200/op.22.00328 · Cited by 94
Kim, S. S. Y., Signorovitch, J., Yang, H., Patterson‐Lomba, O., Xiang, C. Q., Ung, B. L., Parisi, M., & Marshall, J. L. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0784-z · Cited by 83
He, H., Yuan, D., Wu, Y., & Cao, Y. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11030110 · Cited by 80
“It was approved in 2015 by the FDA for intended use in combination with fluorouracil and folinic acid, based in part on its prolonged progression-free and overall survival in the nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI…”
Digestive cancers: mechanisms, therapeutics and management
Zhan, T., Betge, J., Schulte, N., Dreikhausen, L., Hirth, M., Li, M., Weidner, P., Leipertz, A., Teufel, A., & Ebert, M. P. A. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02097-4 · Cited by 90
Pacheco-Barcía, V., Solís, R. M., France, T., Asselah, J., Donnay, O., Zogopoulos, G., Bouganim, N., Guo, K., Rogado, J., Martín, E., et al. (2019) · Pancreatology · doi:10.1016/j.pan.2019.12.010 · Cited by 79
Self-citationClinical Impact of Molecular Subtyping of Pancreatic Cancer
Zhou, X., Hu, K., Bailey, P. J., Springfeld, C., Roth, S., Kurilov, R., Brors, B., Gress, T. M., Buchholz, M., An, J., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.743908 · Cited by 84
“Systemic chemotherapy is the only conventional approach for improving survival in patients with advanced disease with the best achievable median survival rates being 8–12 months for metastatic disease and 12–15 months for locally advanced pancreatic cancer (Burris et al., 1997; Cunningham et al., 2009; Conroy et al.,…”
BackgroundChaudhuri, A., Kumar, D. N., Shaik, R. A., Eid, B. G., Abdel‐Naim, A. B., Md, S., Ahmad, A., & Agrawal, A. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710068 · Cited by 85
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
Lamb, Y. N., & Scott, L. J. (2017) · Drugs · doi:10.1007/s40265-017-0741-1 · Cited by 76
“Serum carbohydrate antigen 19-9 (CA19-9) levels were C40 U/mL in 80% of patients and KPS was C90 in 53% of patients [17, 29].”
BackgroundMethodInfluentialDotan, E., Cardin, D. B., Lenz, H., Messersmith, W. A., O’Neil, B. H., Cohen, S. J., Denlinger, C. S., Shahda, S., Astsaturov, I. A., Kapoun, A. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0489 · Cited by 78
“Nausea 1 (20) 0 0 0 1 (4) Ipafricept-related AE ≥grade 3 1 (20) 2 (29) 2 (29) 1 (14) 6 (23)”
BackgroundNel, A. E., Mei, K., Liao, Y., & Liu, X. (2022) · ACS Nano · doi:10.1021/acsnano.2c01252 · Cited by 81
Dalgleish, A. G., Stebbing, J., Adamson, D. J., Arif, S. S., Bidoli, P., Chang, D., Cheeseman, S., Diaz-Beveridge, R., Fernandez-Martos, C., Glynne-Jones, R., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.271 · Cited by 75
Self-citationBroekgaarden, M., Anbil, S. R., Bulin, A., Obaid, G., Mai, Z., Baglo, Y., Rizvi, I., & Hasan, T. G. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119421 · Cited by 78
Recent advances in prodrug-based nanoparticle therapeutics
Chen, K., Plaunt, A. J., Leifer, F., Kang, J. Y., & Cipolla, D. C. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.04.025 · Cited by 79
Pallares, R. M., Barmin, R. A., Wang, A., Kiessling, F. M., & Lammers, T. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113991 · Cited by 81
Self-assembling peptide-based nanodrug delivery systems
Wang, Q., Jiang, N., Fu, B., Huang, F., & Liu, J. (2019) · Biomaterials Science · doi:10.1039/c9bm01212e · Cited by 74
Huerta, M., Roselló, S., Sabater-Orti, L., Ferrer, A., Tarazona, N., Roda, D., Gambardella, V., Alfaro‐Cervelló, C., Garcés‐Albir, M., Cervantes, A. M. R., et al. (2021) · Cancers · doi:10.3390/cancers13050994 · Cited by 78
Schmitz-Winnenthal, F. H., Hohmann, N., Schmidt, T., Podola, L., Friedrich, T., Lubenau, H., Springer, M., Wieckowski, S., Breiner, K. M., Mikus, G., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1303584 · Cited by 73
“The poor 5-y survival rate of 8% is largely due to the mostly advanced, non-resectable situation at clinical presentation, and to marked resistance to chemotherapy.8-11 Treatment options are limited compared with other cancers, and since 2011, only one drug has been approved by the FDA.12 Several approaches to immunot…”
BackgroundTopoisomerases and cancer chemotherapy: recent advances and unanswered questions
Bjornsti, M., & Kaufmann, S. H. (2019) · F1000Research · doi:10.12688/f1000research.20201.1 · Cited by 74
Chemotherapy in Pancreatic Cancer: A Systematic Review
Hajatdoost, L., Sedaghat, K., Walker, E. J., Thomas, J., & Kosari, S. (2018) · Medicina · doi:10.3390/medicina54030048 · Cited by 74
Advances in Tumor Targeted Liposomes
Jain, A., & Jain, S. (2018) · Current Molecular Medicine · doi:10.2174/1566524018666180416101522 · Cited by 72
Karas, S., & Innocenti, F. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00624 · Cited by 76
Schultheis, B. S., Strumberg, D., Kuhlmann, J. B., Wolf, M., Link, K., Seufferlein, T. T. W., Kaufmann, J., Feist, M., Gebhardt, F., Khan, M., et al. (2020) · Cancers · doi:10.3390/cancers12113130 · Cited by 71
Self-citationSWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer
Botta, G. P., Kato, S., Patel, H., Fanta, P. T., Lee, S., Okamura, R., & Kurzrock, R. (2021) · JCI Insight · doi:10.1172/jci.insight.150453 · Cited by 71
Luo, L., Wang, X., Liao, Y., Chang, C. H., & Nel, A. E. (2022) · ACS Nano · doi:10.1021/acsnano.2c06300 · Cited by 70
miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma
Tesfaye, A. A., Azmi, A. S., & Philip, P. A. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.10.005 · Cited by 72
Pharmacokinetics and pharmacodynamics of liposomal chemophototherapy with short drug-light intervals
Luo, D., Carter, K. A., Molins, E. A. G., Straubinger, N. L., Geng, J., Shao, S., Jusko, W. J., Straubinger, R. M., & Lovell, J. F. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.01.030 · Cited by 70
“cancer after favorable phase III trials results in which it was combined with fluorouracil and folinic acid [10,11].”
Sawada, M., Kasuga, A., Mie, T., Furukawa, T., Taniguchi, T., Fukuda, K., Yamada, Y., Takeda, T., Kanata, R., Matsuyama, M., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06945-8 · Cited by 69
“1 months, respectively, and, indicating a new treatment option for this population [10].”
BackgroundRecent advances in the treatment of pancreatic cancer
Roth, M. T., Cardin, D. B., & Berlin, J. D. (2020) · F1000Research · doi:10.12688/f1000research.21981.1 · Cited by 68
Yang, J., Wang, X., Wang, B., Park, K., Wooley, K. L., & Zhang, S. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114525 · Cited by 67
Liposomes for drug delivery in stroke
Bruch, G. E., Fernandes, L. F., Bassi, B. L. T., Alves, M. T. R., Pereira, I. O., Frézard, F., & Massensini, A. R. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.07.015 · Cited by 68
Taı̈eb, J., Prager, G. W., Melisi, D., Westphalen, C. B., D’Esquermes, N., Ferreras, A., Carrato, A., & Macarulla, T. M. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000587 · Cited by 66
Self-citationChiorean, E. G., Cheung, W. Y., Giordano, G., Kim, G., & Al-Batran, S. E. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919850367 · Cited by 66
Yang, Y., Hu, D., Lu, Y., Chu, B., He, X., Chen, Y., Xiao, Y., Yang, C., Zhou, K., Yuan, L., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.08.021 · Cited by 64
Self-citationHydrogels: 3D Drug Delivery Systems for Nanoparticles and Extracellular Vesicles
Chabria, Y., Duffy, G. P., Lowery, A., & Dwyer, R. M. (2021) · Biomedicines · doi:10.3390/biomedicines9111694 · Cited by 68
“A liposomal Irinotecan is the most recently approved drug carrier that works by passively targeting pancreatic cancer as a topoisomerase I inhibitor [11].”
BackgroundPersister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC
Zhou, X., An, J., Kurilov, R., Brors, B., Hu, K., Peccerella, T., Roessler, S. K., Pfütze, K., Schulz, A., Wolf, S., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00628-6 · Cited by 68
Improving outcomes of patients with pancreatic cancer
Dreyer, S. B., Beer, P. A., Hingorani, S. R., & Biankin, A. V. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01019-9 · Cited by 71
“Nanoliposomal irinotecan combined with 5-fluorouracil and folinic acid (NALIRIFOX) has also demonstrated efficacy in patients with metastatic PDAC, with a median OS of 11.1 months compared with 9.2 months in those who received gemcitabine–nab-paclitaxel 13,14 (Table 1).”
InfluentialCho, I. R., Kang, H., Jo, J. H., Lee, H. S., Chung, M. J., Park, J. Y., Park, S. W., Song, S. Y., An, C., Park, M., et al. (2020) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v12.i2.182 · Cited by 64
Self-citationTranslational considerations in nanomedicine: The oncology perspective
Gabizón, A., de Rosales, R. T. M., & La-Beck, N. M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.012 · Cited by 63
Targeted drug delivery using iRGD peptide for solid cancer treatment
Liu, X., Jiang, J., Ji, Y. C., Lu, J., Chan, R., & Meng, H. (2017) · Molecular Systems Design & Engineering · doi:10.1039/c7me00050b · Cited by 60
An overview on the current status of cancer nanomedicines
Jabir, N. R., Anwar, K., Firoz, C. K., Oves, M., Kamal, M. A., & Tabrez, S. S. M. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1421528 · Cited by 61
Nwabuife, J. C., Pant, A., & Govender, T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113861 · Cited by 61
Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer
Adiwijaya, B., Kim, J., Láng, I., Csőszi, T., Cubillo, A., Chen, J., Wong, M., Park, J. O., Kim, J., Rau, K.-M., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.720 · Cited by 59
Self-citationA comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike?
Katayama, E., Hue, J. J., Bajor, D. L., Ocuin, L. M., Ammori, J. B., Hardacre, J. M., & Winter, J. M. (2020) · Oncotarget · doi:10.18632/oncotarget.27727 · Cited by 58
Wainberg, Z. A., Bekaii‐Saab, T., Boland, P. M., Dayyani, F., Macarulla, T. M., Mody, K., Belanger, B., Maxwell, F., Moore, Y., Thiagalingam, A., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.028 · Cited by 62
Self-citationMichl, P., Löhr, M. J., Neoptolemos, J. P., Capurso, G., Rebours, V., Malats, N., Ollivier, M., & Ricciardiello, L. (2021) · United European Gastroenterology Journal · doi:10.1002/ueg2.12123 · Cited by 60
A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma
Clarke, J. L., Molinaro, A. M., Cabrera, J. R., DeSilva, A. A., Rabbitt, J. E., Prey, J. D., Drummond, D. C., Kim, J., Noble, C. O., Fitzgerald, J. B., et al. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3247-3 · Cited by 58
“Finally, the results of an open-label phase 3 clinical trial testing nal-IRI alone or in combination with fluorouracil and folinic acid in patients with metastatic pancreatic cancer after prior treatment with gemcitabine were recently published [10] and demonstrated improvement in overall survival for the combination,…”
BackgroundSelf-citationCamblin, A. J., Pace, E. A., Adams, S., Curley, M. D., Rimkunas, V. M., Nie, L., Tan, G., Bloom, T., Iadevaia, S., Baum, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2262 · Cited by 57
“Recently, nanoliposomal irinotecan (Onivyde), in combination with fluorouracil and leucovorin, was approved by the US Food and Drug Administration for the treatment of patients with metastatic disease who previously received gemcitabine-based therapy (5, 6).”
BackgroundLysosomal nanotoxicity: Impact of nanomedicines on lysosomal function
Uzhytchak, M., Smolková, B., Lunová, M., Frtús, A., Jirsa, M., Dejneka, A., & Lunov, O. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114828 · Cited by 61
Targeted Nanoparticle-Based Diagnostic and Treatment Options for Pancreatic Cancer
Gu, X., & Minko, T. (2024) · Cancers · doi:10.3390/cancers16081589 · Cited by 60
“These delivery systems exhibit a relatively safe profile, with low occurrences of adverse effects.”
BackgroundQi, C., Zhang, P., Liu, C., Zhang, J., Zhou, J., Yuan, J., Liu, D., Zhang, M., Gong, J., Wang, X., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02314 · Cited by 60
Hendrickson, A. E. W., Menefee, M. E., Hartmann, L. C., Long, H. J., Northfelt, D., Reid, J. M., Boakye‐Agyeman, F., Kayode, O., Flatten, K. S., Harrell, M. I., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1590 · Cited by 57
“Nanoliposomal irinotecan used in combination with 5-fluorouracil and folinic acid has extensive activity against advanced pancreatic cancer (7).”
BackgroundNanotechnology Toward Treating Cancer
Pillai, G. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814029-1.00009-0 · Cited by 60
Greene, M. K., Johnston, M. C., & Scott, C. J. (2021) · Cancers · doi:10.3390/cancers13246175 · Cited by 59
“The approval of Abraxane and Onivyde has now propelled nanomedicine to the forefront of clinical management strategies for PaCa, providing patients with a wider repertoire of treatment options and stimulating intense efforts to further build upon this success.”
BackgroundInfluentialTreatment of metastatic pancreatic cancer: 25 years of innovation with little progress for patients
Gyawali, B., & Booth, C. M. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00516-8 · Cited by 62
KRAS: the Achilles’ heel of pancreas cancer biology
Drizyte‐Miller, K., Talabi, T., Somasundaram, A., Cox, A. D., & Der, C. J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191939 · Cited by 70
Chawla, S. P., Bruckner, H. W., Morse, M. A., Assudani, N., Hall, F. L., & Gordon, E. M. (2018) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2018.12.005 · Cited by 60
Vogl, U. M., Andalibi, H., Klaus, A., Vormittag, L., Schima, W., Heinrich, B., Kafka, A., Winkler, T., & Öhler, L. (2019) · BMC Cancer · doi:10.1186/s12885-018-5240-6 · Cited by 55
“Nal-IRI in combination with 5-FU/leucovorin had shown a benefit in gemcitabine-pretreated patients in the NAPOLI trial [19].”
BackgroundMechanisms and emerging strategies for irinotecan-induced diarrhea
Xu, S., Lan, H., Huang, C.-Y., Ge, X., & Zhu, J. Y. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176614 · Cited by 58
Biscaia-Caleiras, M., Fonseca, N. A., Lourenço, A. S., Moreira, J. N., & Simões, S. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.021 · Cited by 57
Mastrantoni, L., Chiaravalli, M., Spring, A., Beccia, V., Bello, A. D., Bagalá, C., Bensi, M., Barone, D., Trovato, G., Caira, G., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00511-4 · Cited by 61
Riedl, J. M., Posch, F., Horvath, L., Gantschnigg, A., Renneberg, F., Schwarzenbacher, E., Moik, F., Barth, D. A., Rossmann, C. H., Stotz, M., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.040 · Cited by 56
FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021
Sochacka-Ćwikła, A., Mą̨czyński, M., & Regiec, A. (2022) · Molecules · doi:10.3390/molecules27072259 · Cited by 56
A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma
Indolfi, L., Ligorio, M., Ting, D. T., Xega, K., Tzafriri, A. R., Bersani, F., Aceto, N., Thapar, V., Fuchs, B. C., Deshpande, V., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.03.044 · Cited by 55
“A plethora of strategies have been implemented for improving drug delivery e including, liposome formulations [20] and proteins as natural biomaterials to stabilize drug deliverability [21].”
Hossen, M. N., Wang, L., Chinthalapally, H. R., Robertson, J. D., Fung, K.-M. A., Wilhelm, S., Bieniasz, M., Bhattacharya, R., & Mukherjee, P. (2020) · Science Advances · doi:10.1126/sciadv.aba5379 · Cited by 52
Alkan, O., Schoeberl, B., Shah, M., Koshkaryev, A., Heinemann, T., Drummond, D. C., Yaffe, M. B., & Raue, A. (2018) · Science Signaling · doi:10.1126/scisignal.aat0229 · Cited by 51
Petrini, M., Lokerse, W. J. M., Mach, A., Hossann, M., Merkel, O. M., & Lindner, L. H. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s305106 · Cited by 52
Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment
Bhatia, R., Bhyravbhatla, N., Kisling, A., Li, X., Batra, S. K., & Sushil Kumar, K. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.021 · Cited by 52
Yang, X., Zhang, J., Zhou, Q.-M., Yu, J., Lu, Y., Wang, X., Zhou, J.-P., Ding, X.-F., Du, Y., & Yu, R. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01738-6 · Cited by 56
Biopolymer-Based Nanomedicine for Cancer Therapy: Opportunities and Challenges
Wu, X., Xin, Y., Zhang, H., Liang, Q., & Ao, Q. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s460047 · Cited by 56
Zeng, Y., Chen, X., Chen, G., Deng, Z., Tong, Q., Sun, Z., Ma, X., Su, W., Ma, L., Ran, Y., et al. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c11650 · Cited by 51
Hubner, R. A., Cubillo, A., Blanc, J., Melisi, D., Hoff, D. D. V., Wang‐Gillam, A., Chen, L., Becker, C., Mamlouk, K. K., Belanger, B., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.09.029 · Cited by 51
“The NAPOLI-1 study design, methodology and inclusion criteria have been published previously [15].”
BackgroundMethodResultInfluentialSelf-citationCombination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer
Lei, F., Xi, X., Batra, S. K., & Bronich, T. K. (2019) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.255786 · Cited by 51
“…irinotecan with 5-FU and folinic acid demonstrated enhanced RR (16% vs. 1%), prolonged PFS (2.3 months vs. 1.4 months, demonstrated as time to treatment failure), andOS (6.1months vs. 4.2months) compared with the 5-FU/folinic acid regimen with a manageable safety profile (Wang-Gillam et al., 2016).”
BackgroundResultInfluentialEnvironmental Risk Factors of Pancreatic Cancer
Tsai, H., & Chang, J. S.-M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091427 · Cited by 57
Carnevale, J. C., & Ko, A. H. (2015) · Future Oncology · doi:10.2217/fon.15.333 · Cited by 51
Vienot, A., Beinse, G., Louvet, C., de Mestier, L., Meurisse, A., Fein, F., Heyd, B., Cléau, D., d’Engremont, C., Dupont-Gossart, A.-C., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx037 · Cited by 50
“Combinations of 5-FU with oxaliplatin (11) or with nanoliposomal irinotecan (12) have shown interesting activity after failure of gemcitabine and can be proposed as second-line chemotherapy (L2) (8).”
BackgroundYoo, C., Im, H.-S., Kim, K., Oh, D. Y., Lee, K.-H., Chon, H. J., Kim, J. H., Kang, M., Kim, I. H., Lee, G. J., et al. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919871126 · Cited by 50
Self-citationImmunotherapy for Pancreatic Cancer: Present and Future
Aroldi, F., & Zaniboni, A. (2017) · Immunotherapy · doi:10.2217/imt-2016-0142 · Cited by 48
Sheahan, A. V., Biankin, A. V., Parish, C. R., & Khachigian, L. M. (2018) · Oncotarget · doi:10.18632/oncotarget.25085 · Cited by 49
Germline mutations in pancreatic cancer and potential new therapeutic options
Pihlak, R., Valle, J. W., & McNamara, M. G. (2017) · Oncotarget · doi:10.18632/oncotarget.17291 · Cited by 48
Broekgaarden, M., Rizvi, I., Bulin, A., Petrovic, L. Z., Goldschmidt, R., Massodi, I., Celli, J. P., & Hasan, T. G. (2018) · Oncotarget · doi:10.18632/oncotarget.24425 · Cited by 48
“Advances in chemotherapeutic approaches have seen modest success in large placebo-controlled clinical trials [2, 3], the most effective being FOLFIRINOX, a stringent chemotherapy cocktail comprising folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin (OxPt) [1].”
BackgroundTherapeutic targeting of tumor‐associated macrophages in pancreatic neuroendocrine tumors
Krug, S., Abbassi, R., Griesmann, H., Sipos, B., Wiese, D., Rexin, P., Blank, A., Perren, A. A., Haybaeck, J., Hüttelmaier, S., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31562 · Cited by 50
“Generally, nanoparticle-coating of cytotoxic drugs such as doxorubicin or irinotecan with liposomes is increasingly used to decrease toxicity and improve tolerability.(46,47) Despite of the pronounced effects of liposomal clodronate action on microvessel density and tumor progression, we failed to detect a significant…”
BackgroundPicozzi, V. J., Oh, S. Y., Edwards, A. M., Mandelson, M. T., Dorer, R. K., Rocha, F. G., Alseidi, A. A., Biehl, T. A., Traverso, L. W., Helton, W. S., et al. (2017) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5716-z · Cited by 47
Bang, Y., Li, C., Lee, K., Chiu, C., Park, J. O., Shan, Y., Kim, J. S., Chen, J., Shim, H., Rau, K., et al. (2019) · Cancer Science · doi:10.1111/cas.14264 · Cited by 47
Self-citationUeno, M., Nakamori, S., Sugimori, K., Kanai, M., Ikeda, M., Ozaka, M., Furukawa, M., Okusaka, T., Kawabe, K., Furuse, J., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3558 · Cited by 47
Metadata
- Authors
- Wang-Gillam, A., Li, C.-P., Bodoky, G., Dean, A., Shan, Y.-S., Jameson, G., Macarulla, T., Lee, K.-H., Cunningham, D., Blanc, J. F., Hubner, R. A., Chiu, C.-F., Schwartsmann, G., Siveke, J. T., Braiteh, F., Moyo, V., Belanger, B., Dhindsa, N., Bayever, E., Von Hoff, D. D., Chen, L.-T., Adoo, C., Anderson, T., Asselah, J., Azambuja, A., Bampton, C., Barrios, C. H., Bekaii-Saab, T., Bohuslav, M., Chang, D., Chen, J.-S., Chen, Y.-C., Choi, H. J., Chung, I. J., Chung, V., Csoszi, T., Cubillo, A., DeMarco, L., de Wit, M., Dragovich, T., Edenfield, W., Fein, L. E., Franke, F., Fuchs, M., Gonzales-Cruz, V., Gozza, A., Fernando, R. H., Iaffaioli, R., Jakesova, J., Kahan, Z., Karimi, M., Kim, J. S., Korbenfeld, E., Lang, I., Lee, F.-C., Lee, K.-D., Lipton, L., Ma, W. W., Mangel, L., Mena, R., Palmer, D., Pant, S., Park, J. O., Piacentini, P., Pelzer, U., Plazas, J. G., Prasad, C., Rau, K.-M., Raoul, J.-L., Richards, D., Ross, P., Schlittler, L., Smakal, M., Stahalova, V., Sternberg, C., Seufferlein, T., Tebbutt, N., Vinholes, J. J., Wadlow, R., Wenczl, M., & Wong, M.
- Affiliations
- Taipei Veterans General Hospital (TW)
- St John of God Subiaco Hospital (AU)
- National Cheng Kung University Hospital (TW)
- Translational Genomics Research Institute (US)
- Vall d'Hebron Institute of Oncology (ES)
- Seoul National University Hospital (KR)
- Royal Marsden Hospital (GB)
- Hôpital Saint-André (FR)
- The Christie NHS Foundation Trust (GB)
- China Medical University Hospital (TW)
- Hospital de Clínicas de Porto Alegre (BR)
- TUM Klinikum (DE)
- Comprehensive Cancer Centers of Nevada (US)
- Merrimack Pharmaceuticals (United States) (US)
- Kaohsiung Medical University (TW)
- Corresponding author
- Chen, Li-Tzong
- ORCID
- Li, Chung-Pin
- Dean, Andrew
- Shan, Yan-Shen
- Jameson, Gayle
- Macarulla, Teresa
- Lee, Kyung-Hun
- Cunningham, David
- Hubner, Richard A
- Schwartsmann, Gilberto
- Siveke, Jens T
- Braiteh, Fadi
- Moyo, Victor
- Belanger, Bruce
- Chen, Li-Tzong
- Asselah, Jamil
- Barrios, Carlos Henrique
- Chang, David
- Chen, Jen-Shi
- Chen, Yeu-Chin
- Choi, Hye Jin
- Chung, Vincent
- Cubillo, Antonio
- Dragovich, Tomislav
- Fein, Luis Enrique
- Fuchs, Martin
- Korbenfeld, Ernesto
- Lee, Fa-Chyi
- Lee, Kuan-Der
- Ma, Wen Wee
- Palmer, Daniel
- Pant, Shubham
- Park, Joon Oh
- Pelzer, Uwe
- Rau, Kun-Ming
- Raoul, Jean-Luc
- Richards, Donald
- Ross, Paul
- Stahalova, Vladimira
- Sternberg, Cora
- Seufferlein, Thomas
- Tebbutt, Niall
- Wadlow, Raymond
- Wong, Mark
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2016-02
- Volume
- 387
- Issue
- 10018
- Pages
- 545-557
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2187917981
- Cited by
- 1,222
- References
- 29
- Citations by year
- 2026: 92 · 2025: 123 · 2024: 122 · 2023: 116 · 2022: 119 · 2021: 156 · 2020: 117 · 2019: 116 · 2018: 99 · 2017: 101 · 2016: 53
- FWCI
- 37.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- 5-fluorouracil, leucovorin, metastatic pancreatic ductal adenocarcinoma, gemcitabine-refractory disease, combination chemotherapy, overall survival, first-line therapy, NAPOLI-1 trial, albumin, Karnofsky performance status
- MeSH terms
- Irinotecan, Gemcitabine, Aged, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Deoxycytidine, Diarrhea, Fatigue, Female, Fluorouracil, Humans, Liposomes, Male, Middle Aged, Neoplasm Metastasis, Neutropenia, Pancreatic Neoplasms, Vomiting, Treatment Outcome, Carcinoma, Pancreatic Ductal, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
